Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 82009-182

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 82009-182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

This text contains information about a medication in tablet form called clopidogrel bisulfate, each tablet equivalent to 75 mg of the active ingredient. The usual adult dosage is not specified in the text, but there is a reference to checking the package insert for guidance. It emphasizes storing the tablets in well-closed containers at 25°C (77°F) with permitted excursions to 15-30°C (56-86°F). The text also mentions a requirement for pharmacists to dispense a Medication Guide to each patient. For more information, patients are directed to visit the manufacturer's website.*

FDA Label Image

Figure1 (Figure1)

This text provides information on the effect of co-administered PPIs on the active metabolite AUC (area under the concentration-time curve) along with their mean and 90% confidence intervals. The specific PPIs evaluated are Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole at different doses. The data is presented in a tabular format with values for each PPI dosage.*

FDA Label Image

Figure2 (Figure2)

This text provides information on a clinical trial comparing Clopidogrel plus aspirin to a placebo plus aspirin. The cumulative event rates over a period of 7 months of follow-up are shown. Other standard therapies were also used as appropriate in the trial.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This text provides comparative data on the mortality rates of patients receiving a placebo versus those receiving Clopidogrel. A 7% proportional risk reduction in mortality was observed with Clopidogrel. The study had a duration of up to 28 days since randomization. The statistical significance of this risk reduction was found to be p=0.03.*

FDA Label Image

Figure5 (Figure5)

This text appears to be presenting statistical data related to the outcomes of patients in a study comparing the effectiveness of two treatments in reducing the risk of death, reinfarction, or stroke before discharge. The data suggests that clopidogrel had a 9% proportional risk reduction compared to a placebo, with 10.1% of those in the placebo group experiencing an event compared to 9.2% in the clopidogrel group. The statistical significance is reported as p=0.002. The information also indicates that the evaluation was carried out up to 28 days following randomization of the patients.*

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

Not available.*

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.